A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects aged 18 Years and Older with Cystic Fibrosis
|Effective start/end date
|6/1/19 → 7/31/22
- VERTEX PHARMACEUTICALS INCORPORATED
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.